EIC Accelerator

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

AptaTargets is a biopharmaceutical company developing therapeutic applications based on aptamer technology. The company advances drug candidates from preclinical stages toward clinical development with the aim of reaching phase 2 trials. Its approach uses aptamers to recognize specific therapeutic targets, offering an antibody-like mechanism with potential advantages in precision and safety. The pipeline addresses inflammatory and neuroprotective indications, including conditions such as ischemic stroke, myocardial infarction, and autoimmune diseases, and seeks to modulate disease pathways through targeted molecular recognition.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Celtic Biotech is a biotechnology company focused on developing innovative therapies for the treatment of solid cancers and pain in humans. Co-founded by John Reid, the company utilizes specialized receptor-binding proteins derived from snake venom to create its therapeutic products. These novel candidate therapies aim to enhance patient survival rates, improve quality of life, and reduce the overall costs of cancer treatment. By leveraging unique biological mechanisms, Celtic Biotech addresses significant medical challenges in oncology and pain management.

Thirona is a software company that develops AI-powered medical imaging analysis tools and provides image analysis services for the healthcare industry. Its automated tools support the analysis of thoracic CT scans, chest X-rays, and retinal images, delivering accurate and repeatable measurements to help hospitals detect and mitigate diseases. The company offers software solutions and certified image analysis services that streamline imaging workflows and improve diagnostic precision.

BioSimulytics is a company that specializes in creating AI-powered software tailored for drug researchers in the pharmaceutical industry. Its innovative platform integrates molecular chemistry, quantum physics, and advanced artificial intelligence to enhance the drug development process. By focusing on crystal-structure prediction, BioSimulytics enables researchers to accurately predict stable polymorphs, which significantly improves the speed, certainty, and quality of product data. This technology aims to streamline the development of pharmaceuticals, ultimately supporting researchers in their quest to bring new drugs to market more efficiently.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

ReST Therapeutics is a clinical biotechnology company focused on developing innovative therapies for complex central nervous system (CNS) disorders. Utilizing its patented medication candidate, the company aims to create treatments that selectively target NMDA receptors, with the intention of addressing conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. By advancing its candidate through non-clinical testing, ReST Therapeutics seeks to improve the efficacy of cognitive preservation and provide protection against neurotoxicity, thereby enhancing therapeutic outcomes for patients suffering from these debilitating neural disorders.

MultiplexDX develops accurate, specific, quantifiable diagnostic tests combining molecular biology and histopathological methods. Based in Kosice, Slovakia and Gaithersburg, Maryland, USA, it aims to improve cancer diagnosis and treatment.

MaxiVAX is a Swiss clinical-stage biotechnology company developing personalized cancer immunotherapies. Its lead product, MVX-ONCO-1, is an advanced therapeutic product for various tumors, currently in phase I trials.